Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Targeting CARM1 in ovarian cancer with EZH2 and PARP inhibitors.

Literature DB >> 32944622

Targeting CARM1 in ovarian cancer with EZH2 and PARP inhibitors.

Abstract

Coactivator-associated arginine methyltransferase 1 (CARM1)-expressing high-grade serous ovarian cancers are characterized by poor prognosis and limited therapeutic options. Here we discuss a novel therapeutic strategy to target CARM1-expressing ovarian cancer based on a combination of poly (ADP-ribose) polymerase (PARP) and enhancer of zeste homology 2 (EZH2) inhibitors.

Entities: Disease Gene

Keywords: coactivator-associated arginine methyltransferase 1 (CARM1); enhancer of zeste homology 2 (EZH2) inhibitors; epithelial ovarian cancer; homologous recombination (HR); immune checkpoint blockers; mitotic arrest deficient 2 like 2 (MAD2L2); non-homologous end-joining (NHEJ); poly (ADP-ribose) polymerase (PARP) inhibitors

Year: 2020 PMID： 32944622 PMCID： PMC7469455 DOI： 10.1080/23723556.2020.1760675

Source DB: PubMed Journal: Mol Cell Oncol ISSN： 2372-3556

7 in total

1. EZH2 Inhibition Sensitizes CARM1-High, Homologous Recombination Proficient Ovarian Cancers to PARP Inhibition.

Authors: Sergey Karakashev; Takeshi Fukumoto; Bo Zhao; Jianhuang Lin; Shuai Wu; Nail Fatkhutdinov; Pyoung-Hwa Park; Galina Semenova; Stephanie Jean; Mark G Cadungog; Mark E Borowsky; Andrew V Kossenkov; Qin Liu; Rugang Zhang
Journal: Cancer Cell Date: 2020-01-30 Impact factor: 31.743

Review 2. Combined PARP and Immune Checkpoint Inhibition in Ovarian Cancer.

Authors: Elizabeth K Lee; Panagiotis A Konstantinopoulos
Journal: Trends Cancer Date: 2019-07-15

Review 3. Protein arginine methyltransferases and cancer.

Authors: Yanzhong Yang; Mark T Bedford
Journal: Nat Rev Cancer Date: 2012-12-13 Impact factor: 60.716

4. HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer.

Authors: Takeshi Fukumoto; Nail Fatkhutdinov; Joseph A Zundell; Evgenii N Tcyganov; Timothy Nacarelli; Sergey Karakashev; Shuai Wu; Qin Liu; Dmitry I Gabrilovich; Rugang Zhang
Journal: Cancer Res Date: 2019-07-16 Impact factor: 12.701

5. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy.

Authors: Sangeeta Goswami; Irina Apostolou; Jan Zhang; Jill Skepner; Swetha Anandhan; Xuejun Zhang; Liangwen Xiong; Patrick Trojer; Ana Aparicio; Sumit K Subudhi; James P Allison; Hao Zhao; Padmanee Sharma
Journal: J Clin Invest Date: 2018-07-30 Impact factor: 14.808

6. BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.

Authors: Hengrui Zhu; Fee Bengsch; Nikolaos Svoronos; Melanie R Rutkowski; Benjamin G Bitler; Michael J Allegrezza; Yuhki Yokoyama; Andrew V Kossenkov; James E Bradner; Jose R Conejo-Garcia; Rugang Zhang
Journal: Cell Rep Date: 2016-09-13 Impact factor: 9.423

7. Structural absorption by barbule microstructures of super black bird of paradise feathers.

Authors: Dakota E McCoy; Teresa Feo; Todd Alan Harvey; Richard O Prum
Journal: Nat Commun Date: 2018-01-09 Impact factor: 14.919

7 in total

1 in total

Review 1. Combined inhibition of PARP and EZH2 for cancer treatment: Current status, opportunities, and challenges.

Authors: Xi Zhang; Xiao Huo; Hongyan Guo; Lixiang Xue
Journal: Front Pharmacol Date: 2022-10-03 Impact factor: 5.988

1 in total